Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients
Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients TORONTO, ON / February
February 3, 2022
Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients TORONTO, ON / February
Fish on acid? Microdosing zebrafish with LSD shows its potential benefits for humans New research suggests
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder MindMed’s LSD-based compound
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment
How Do Psychedelics Change Your Personality? These Researchers Tried To Find Out Researchers developed a
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic
World’s Largest Mobile Microdosing Study Published in Nature Scientific Reports Quantified Citizen is a platform
Study suggests psychedelics promote positive mental health through increased spirituality and emotion regulation A recent
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase
Mescaline-Like Psychedelic Alters Synaptic Plasticity Researchers discovered that DOI (a psychedelic that’s similar to LSD
Ayahuasca users report psychological benefits after taking placebo at a ritualistic ceremony An ayahuasca retreat
Allied Corp Progresses Towards Clinical Phase I Trial for Psilonex™ RX Psilocybin Pharma Drug Allied
Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia San Diego, California–(Newsfile
Psilocybin-assisted psychotherapy might help to reduce attachment anxiety A new study suggests that psilocybin therapy
World-first psilocybin clinical trial in the treatment of Generalised Anxiety Disorder receives ethics approval This
Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program Cybin (CYBN) is sending therapists on
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies This week, Cybin Inc. (CYBN) completed
Mushroom Consumption May Lower Risk of Depression Even non-psychedelic mushrooms could lower your risk of
Novamind Launches New Psychedelic Palliative Care Program Patients in palliative care have higher rates of
BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS BRINGS DIGITAL MENTAL HEALTH TECHNOLOGY TO PSYCHEDELICS CLINICAL TRIALS Could microdosing
MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration A new study found
Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data Mydecine Innovations Group (MYCO)